Filter by Event: Infectious Disease Society of America IDWeek 2017
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014-2016)
Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1215
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers (2013-2016)
Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers (2013-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1232
Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe during 2014-2016 as Part of a Global Surveillance Program
Activity of Delafloxacin When Tested against Bacterial Surveillance Isolates Collected in the US and Europe during 2014-2016 as Part of a Global Surveillance Program, Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1222
Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010-2016)
Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1239
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1216
Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing
Activity of Plazomicin against Enterobacteriaceae Isolates Collected in the United States Including Isolates Carrying Aminoglycoside-Modifying Enzymes Detected by Whole Genome Sequencing, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1235
Ceftobiprole Activity When Tested against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
Ceftobiprole Activity When Tested against Contemporary Bacteria Causing Bloodstream Infections in the US (2016), Lead author: Flamm RK, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1205
Yearly Trends of Antimicrobial Nonsusceptibility among Streptococcus pneumoniae Serotypes Causing Infection in Adult Patients in the United States (2009-2015)
Yearly Trends of Antimicrobial Nonsusceptibility among Streptococcus pneumoniae Serotypes Causing Infection in Adult Patients in the United States (2009-2015), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1496
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States Medical Centers Stratified by Infection Type (2015-2016)
Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Tested against Enterobacteriaceae and Pseudomonas aeruginosa from United States Medical Centers Stratified by Infection Type (2015-2016), Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1237
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2106): Results from the SENTRY Antimicrobial Surveillance Program
In vitro Evaluation of Delafloxacin Activity When Tested against Contemporary Community-Acquired Bacterial Respiratory Tract Infection Isolates (2014-2106): Results from the SENTRY Antimicrobial Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1208
Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008-2016)
Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008-2016), Lead author: Pfaller MA, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1207
Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: 8 Years of US Surveillance (2009-2016)
Distributions and Annual Changes of Streptococcus pneumoniae Serotypes Causing Infections in Adult Patients: 8 Years of US Surveillance (2009-2016), Lead author: Arends SJR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1500
Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States Medical Centers (2011-2016)
Antimicrobial Activity of Dalbavancin and Comparator Agents Tested against Gram-Positive Clinical Isolates Causing Bone and Joint Infections in United States Medical Centers (2011-2016), Lead Author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1221
Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-Negative Organisms Causing Bloodstream Infections Worldwide
Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-Negative Organisms Causing Bloodstream Infections Worldwide, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1226
Activity of Meropenem-Vaborbactam (VABOMERETM) against Enterobacteriaceae Isolates carrying blakpc Collected Worldwide
Activity of Meropenem-Vaborbactam (VABOMERETM) against Enterobacteriaceae Isolates carrying blakpc Collected Worldwide, Lead author: Castanheira, M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1234
In Vitro Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program
In Vitro Activity of Omadacycline and Comparator Compounds against Gram-Positive Isolates Collected in the US During 2016 as Part of a Global Surveillance Program, Lead author: Huband MD, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1223
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs Non-ICU Respiratory Isolates Collected in US Medical Centers
Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2012-2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs Non-ICU Respiratory Isolates Collected in US Medical Centers, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1198
Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014-2016)
Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014-2016), Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1210
Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012-2016 as Part of a Global Surveillance Program
Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012-2016 as Part of a Global Surveillance Program, Lead author: Shortridge D, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1202
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents Tested against Contemporary (2016) Clinical Enterobacteriaceae Isolates, Lead author: Sader HS, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #1233
Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States Medical Centers
Antimicrobial Activity of Dalbavancin Tested against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from United States Medical Centers, Lead author: Sader HS, presented at IDWeek 2017, October 4-7, San Diego, CA, USA
Poster #1238
Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Gram-Negative Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials
Molecular Characterization of Fluoroquinolone Resistance Mechanisms in Gram-Negative Isolates from the Delafloxacin Acute Bacterial Skin and Skin Structure Infections Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #331
Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox® Annual Appraisal of Potency and Spectrum Program for 2016
Sustained In Vitro Activity of Linezolid and Evolving Resistance Mechanisms: Summary of the Zyvox® Annual Appraisal of Potency and Spectrum Program for 2016, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #329
Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials
Characterization of β-Lactam Resistance Mechanisms among Baseline Pseudomonas aeruginosa from 5 Ceftazidime-Avibactam Phase 3 Clinical Trials, Lead author: Mendes RE, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #326
Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016)
Regional Analysis of Resistance Phenotypes among Staphylococcus aureus Causing Infections in US Census Divisions: Telavancin Activity against Resistant Pathogens (2014-2016), Lead author: Duncan LR, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #333
Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents
Characterization of Enterobacter and Citrobacter spp. Isolates from United States Hospitals by Whole Genome Sequencing Analysis and Activity of Ceftazidime-Avibactam and Comparator Agents, Lead author: Castanheira M, presented at IDWeek 2017, October 4-8, San Diego, CA, USA
Poster #320
